When will the COVID-19 ワクチン be rolled out and who will get it first? Everything you need to know about Pfizer's 打開 発射

  • Pfizer, which developed a ワクチン with German drugmaker BioNTech, is the first to 解放(する) successful data based on an 暫定的な 分析?
  • The 告示 燃料d hope that the 全世界の pandemic could come to an end as Pfizer あられ/賞賛するd the ワクチン victory a '広大な/多数の/重要な day for science and humanity'?
  • The US has already paid $1.95 billion for 100 million 初期の doses of the ワクチン?
  • Pfizer says it could have up to 50 million doses 利用できる by the end of this year if 認可するd?
  • So what do you need to know about Pfizer's ワクチン??

The 全世界の race to find a COVID-19 ワクチン took a leap 今後 today when US drugmaker Pfizer 明らかにする/漏らすd its jab is 90 パーセント 効果的な.?

Pfizer, which developed a ワクチン with German drugmaker BioNTech, is the first to 解放(する) successful data based on an 暫定的な 分析 from a large-規模 coronavirus ワクチン 臨床の 裁判,公判.

The 告示 from the two pharma companies 燃料d hope that the 全世界の pandemic could come to an end as Pfizer あられ/賞賛するd the ワクチン victory a '広大な/多数の/重要な day for science and humanity'.?

The 部隊d 明言する/公表するs has already paid $1.95 billion for 100 million 初期の doses of the ワクチン and Pfizer says it could have up to 50 million doses 利用できる by the end of this year if 認可するd.?

So what do you need to know about Pfizer's ワクチン????

Pfizer, which developed a vaccine with German drugmaker BioNTech, are the first to release successful data based on an interim analysis from a large-scale coronavirus vaccine clinical trial

Pfizer, which developed a ワクチン with German drugmaker BioNTech, are the first to 解放(する) successful data based on an 暫定的な 分析 from a large-規模 coronavirus ワクチン 臨床の 裁判,公判

DOES THIS MEAN A VACCINE IS READY?

Not やめる yet.?

Pfizer has 解放(する)d 予選 findings that 示唆するs its ワクチン is more than 90 パーセント 効果的な in 妨げるing COVID-19.?

The ワクチン has been 実験(する)d on nearly 44,000 people in six different countries and no safety 関心s have been raised so far.?

Pfizer is now planning to 適用する to the Food and 麻薬 行政 for 緊急 是認 to use the ワクチン by the end of the month.?

WHEN COULD IT BE READY FOR THE PUBLIC?

The general public will not 利益 from the ワクチン - if it is 認可するd - for weeks or months to come.

Pfizer said they will try to 適用する for FDA 是認 within the next month if all goes 井戸/弁護士席 with the 残り/休憩(する) of their 裁判,公判.?

The FDA's 科学の 助言者s will 審議 each company's 熟考する/考慮する findings in a public 会合 before the 機関 decides.

製造業者s already have begun 備蓄(する)ing ワクチン doses in 予期 of 結局の 是認 but the first 発射s will be in short 供給(する) and rationed.

Pfizer 推定する/予想するs to produce up to 50 million doses, or enough to 保護する 25 million people, by the end of this year.?

They?推定する/予想する to produce up to 1.3 billion doses of the ワクチン next year.

HOW MANY DOSES HAS THE US BOUGHT?

The 部隊d 明言する/公表するs has already paid $1.95 billion for 100 million 初期の doses of the ワクチン.?

It is enough to 扱う/治療する 50 million Americans.?

世界保健機構 WILL GET IT FIRST?

There is no 公式の/役人 政府 告示 on who will get the COVID-19 ワクチン first.?

A 連邦の (a)忠告の/(n)警報 that is putting together rec ommendations to be 認可するd by the CDC is 現在/一般に considering four groups to かもしれない recommend for 早期に COVID-19 ワクチン接種 if 供給(する) is 限られた/立憲的な.

They 含む:?Healthcare 職員/兵員, 労働者s in 必須の and 批判的な 産業s, people at high 危険 for 厳しい COVID-19 illness 予定 to underlying 医療の 条件s and people 65 years and older.?

HOW DOES THE TRIAL WORK????

Nearly 44,000 people are 入会させるd in Pfizer's final 実験(する)ing of the ワクチン.?

Neither 関係者s, their doctors or Pfizer know who gets the real ワクチン and who gets a 模造の 発射.?

They get a second dose about three weeks after the first and 跡をつけるing begins a week after the second dose.

The 跡をつけるing 伴う/関わるs counting anyone who experiences COVID-19 symptoms and 実験(する)s 肯定的な for the ウイルス as 関係者s go about their daily 決まりきった仕事s, 特に in hotspots.??

WHAT DO THE NEW TRIAL RESULTS SHOW?

The companies?said that 94 people in the 裁判,公判 have so far 実験(する)d 肯定的な for COVID-19.?

Over 90 パーセント 有効性 暗示するs that no more than eight of the 94 people who caught COVID-19 had been given the ワクチン.?

Doing the math, that would mean almost all the 感染s counted so far had to have occurred in people who got the 模造の 発射s.??

The efficacy 率 is 井戸/弁護士席 above the 50 パーセント 有効性 要求するd by the Food and 麻薬 行政 for a ワクチン.

To 確認する the efficacy 率, Pfizer said it will continue the 裁判,公判 until there are 164 COVID-19 事例/患者s の中で 関係者s.?

The FDA has also said companies must 跡をつける half their 関係者s for 味方する 影響s for at least two months, whi ch Pfizer says it 推定する/予想するs to reach later this month.?

HOW TO TELL IF THE VACCINE WORKS??

Every ワクチン 熟考する/考慮する is overseen by an 独立した・無所属 board that 含む scientists and statisticians who have no 関係 to the ワクチン 製造者s.??

Before a 熟考する/考慮する is 完全にする, only the board has the 力/強力にする to 打ち明ける the code of who got real ワクチン and who got placebo and to recommend if the 発射s are working 井戸/弁護士席 enough to stop 実験(する)ing 早期に.

Those boards take こそこそ動く peeks at pre-決定するd times agreed to by the 製造業者 and the FDA.?

The first 暫定的な 分析 for Pfizer (機の)カム on Sunday.?

The company 報告(する)/憶測d its data 監視するs had counted 94 感染s so far - and that の中で those 初期の 事例/患者s, the ワクチン appeared 90 パーセント 効果的な.

To be sure of 保護, the 熟考する/考慮する is 始める,決める to run until there are 164 感染s. The more COVID-19 事例/患者s occur in the 裁判,公判, the better idea scientists will have of just how 保護の the 発射s really are.

COULD THAT SNEAK PEEK HAVE COME EARLIER???

Pfizer's 初期の 計画(する)s called for 評価するing when just 32 感染s had been counted. Many scientists, however, 警告するd that was 簡単に too small to draw 結論s about a ワクチン needed by billions.

Pfizer said it 再考するd, going 支援する to the FDA for 許可 to change the 計画(する) and do its first 暫定的な 分析 when there were more 事例/患者s.?

By the time Pfizer made the change and caught up with a backlog of ウイルス 実験(する)s, the board had 94 感染s to 分析する.

Moderna, AstraZeneca and other companies not やめる as far along in their final 実験(する)ing all have 始める,決める わずかに different timepoints for when their data 監視するs will peek at how the 発射s are working.

The comments below have not been 穏健なd.

The 見解(をとる)s 表明するd in the contents above are those of our 使用者s and do not やむを得ず 反映する the 見解(をとる)s of MailOnline.

We are no longer 受託するing comments on this article.